Thereafter, 100 mcg should be injected once a month for life
Why peptide protocols specify it: A reconstituted 5 mg peptide vial at 2.5 mg/mL holds 20 doses at 250 mcg each
2 A monogenic type of EDS, previously called tenascin-X (TN-X) deficient EDS, was first reported in 1997
Observed responses in research settings are generally reported as mild and may include: Temporary injection-site irritation Redness or warmth sensations Skin-sensitivity variability Temporary blue-tinted discoloration beneath the administration area Localized irritation depending on dosage range, concentration, administration frequency, protocol duration, and individual sensitivity Research protocols commonly investigate daily administration ranges between: 12mg daily in standard research settings Up to 3mg daily in more advanced experimental protocols GHK-Cu is frequently explored in continuous or maintenance-style research structures and does not always require strict cycling protocols in moderate-dose experimental models
This stacking guide covers the rationale, safety basis, administration strategy, and physician-supervised framework for running these two compounds together
Confirm the current product details and match any available documentation to the item before ordering